HIV感染献血者并发感染HBV、HCV及梅毒调查分析

目的:了解曲靖市无偿献血人群中艾滋病病毒(HIV)感染者并发感染乙型肝炎病毒(HBV)、丙型肝炎病毒(HCV)和梅毒的状况。方法:应用酶联免疫吸附试验(ELISA),对HIV感染献血者检测HBsAg、抗-HCV、抗-TP。结果:133例HIV感染献血者中,HBV感染率为1.5%,HCV感染率为10.5%,梅毒感染率为7.5%。结论:曲靖市HIV感染的献血者中,并发HCV和梅毒感染率高,而并发HBV感染率较低。     

河北省HIV-1感染者中HCV和HBV合并感染状况调查

目的了解河北省艾滋病病毒Ⅰ型(HIV-1)感染者中,丙型肝炎病毒(HCV)、乙型肝炎(乙肝)病毒(HBV)的感染状况。方法采集了HIV-1感染者的抗凝全血样品,进行了HCV抗体和乙肝病毒表面抗原(HBsAg)的检测。结果 147例HIV-1感染者中,HCV感染率为17.7%(26/147),HBV感染率为15.0%(22/147),HCV/HBV混合感染率为3.4%(5/147)。在HIV-1感染者中,HCV的感染率在注射吸毒感染者中为100%(6/6),血液途径感染者中为73.3%(11/15),性感染者中为6.3%(7/111),不同感染途径间的差异有统计学意义(P<0.001);女性高于男性(P=0.002);低文化程度的感染者中感染率较高,文化程度方面差异有统计学意义(P<0.01)。在HIV-1感染者中,HBV的感染率小年龄组较高(P<0.05)。结论在HIV感染人群中,有较高的HCV和HBV感染率。     

有偿献血员中艾滋病病毒、乙型肝炎和丙型肝炎病毒感染状况的研究

目的 探讨有偿献血员艾滋病病毒(HIV)、丙型肝炎(丙肝)病毒(HCV)、乙型肝炎(乙肝)病毒(HBV)感染的特点。方法61份HIV阳性献血员及89份HIV阴性献血员的血清,经酶联免疫吸附试验(ELISA)检测HCV抗体(抗-HCV)及HBV血清学标志物,比较两组人群的HCV、HBV及HCV/HBV感染情况。结果HIV阳性献血员的抗-HCV阳性率为70.49％。乙肝病毒表面抗原(HBsAg)与抗体(抗-HBs)、乙肝病毒e抗原(HBeAg)与抗体(抗-HBe)、乙肝病毒核心抗体(抗-HBc)和HBV的阳性率分别为8.20％、29.51％、3.28％、44.26％、11.4896、47.54％;而HIV阴性献血员的抗-HCV阳性率为19.10％,HBsAg、抗-HBs、HBeAg、抗-HBe、抗-HBc、HBV的阳性率分别为2.25％、38.20％、1.12％、47.19％、6.74％、47.19％。经统计学分析,两组人群的HCV、HCV/HBV感染率的差异有显著的统计学意义,而HBV血清学标志物则无显著性差异。结论 与HIV阴性献血员相比。HIV阳性献血员的HCV感染率很高,而HBV血清学标志物则无显著性差异。对献血员进行HBV检测而未检测HIV、HCV造成的选择偏倚,可能是中国中部一些省份HIV感染者HCV感染率高而HBV感染并不相应增高这一现象的原因之一。     

有偿献血员中艾滋病病毒、乙型肝炎和丙型肝炎病毒感染状况的研究

目的：探讨有偿献血员艾滋病病毒（HIV）、丙型肝炎（丙肝）病毒（HCV）、乙型肝炎（乙肝）病毒（HBV）感染的特点，方法：71份HIV阳性献血员及89份HIV阴性献血员的血清，经酶联免疫吸附试验（ELISA）检测HCV抗体（抗－HCV）及HBV血清学标志物，比较两组人群的HCV、HBV及HCV／HBV感染情况，结果：HIV阳性献血员的抗－HCIV阳性率为70．49％，乙肝血清学标志物，比较两组人群的HCV、HBV及HCV／HBV感染情况。结果：HIV阳性献血员的抗－HCV阳性率为70．49％，地病毒表面抗原（HBsAg）与抗体（抗－HBs）、乙肝病毒e抗原（HBeAg）与抗体（抗－HBe)、乙肝病毒核心抗体（抗－HBc）和HBV的阳性率分别为8．20％、29．51％、3．28％、44．26％，11．48％、47．54％、1．12％、47．19％、6．74％、47．19％。经统计学分析，两组人群的HCV、HCV／HBV感染率的差异有显著的统计学意义，而HBV血清学标志物则无显著性差异。结论：与HIV阴性献血员相比，HIV阳性献血员的HCV感染率很高，而HBV血清学标志物则无显著性差异，对献血员进行HBV检测而未检测HIV、HCV造成的选择偏倚，可能是中国中部一些省份HIV感染者HCV感染率高而HBV感染并不相应增高这一现象的原因之一。     

广西桂中地区艾滋病患者乙型和丙型肝炎病毒感染调查研究

目的了解广西桂中地区人类免疫缺陷病毒(HIV)/艾滋病(AIDS)患者合并乙型肝炎病毒(HBV)、丙型肝炎病毒(HCV)感染的情况。方法调查分析我院2007-01～2009-12确诊的2 342例AIDS患者临床资料。结果 HIV/HBV、HIV/HCV、HIV/HBV/HCV共感染率分别为16.8%、22.5%、2.5%,其中吸毒和性传播者HIV/HCV感染率分别为74.7%和8.0%、HIV/HBV感染率分别为15.6%和17.2%、HIV/HBV/HCV感染率分别为7.8%和1.0%。结论广西桂中地区HIV/HBV共感染在性传播和吸毒传播者中差异无统计学意义,HIV/HCV、HIV/HBV/HCV共感染差异有统计学意义,应采取措施控制其传播。     

北京市上地医院流动人口孕产妇中4种传染病的流行病学调查

目的 调查北京市上地医院流动人口孕产妇中HBV、HCV、HIV和梅毒感染情况,为有效阻断母婴传播提供依据.方法 对2007-2010年到上地医院就诊的26 819例流动人口孕产妇的血清进行HBV、HCV、HIV和梅毒抗体检测.结果 26 819例中,HBsAg阳性率为1.70％,抗HCV阳性率为0.03％,HIV抗体阳性率为0.01％,梅毒感染率为0.15％.结论 揭示了北京市流动人口孕产妇中HBV、HCV、HIV、梅毒感染血清流行病学特征.建议孕产妇进行HBV、HCV、HIV、梅毒血清学检查,早发现、早治疗,阻断母婴传播,以利于优生优育.     

经血和经性传播的人类免疫缺陷病毒感染者乙、丙型肝炎病毒重叠感染比较

我国目前传播人类免疫缺陷病毒(HIV)主要途径为经血传播,如静脉吸毒,输血等,我们曾报道了经血传播HIV和HBV/HCV重叠感染的特征[1,2 ] 。而国外报道HIV传播的主要途径为性途径,在经性途径传播的HIV感染者中HBV/HCV重叠感染状况和感染特征不甚明确,我们以HIV感染的德国男性同性恋者为研究对象,首先对其HBV/HCV重叠感染状况进行调查,并总结了经性和经血传播HIV感染者HBV/HCV重叠感染特点及差异。对象和方法一、研究对象1992年1月～2 0 0 0年12月HIV感染的德国男性同性恋者4 9例,我国经血传播HIV感染者6 2例,取静脉血3ml,- …     

有偿供血员HCV、HIV和HBV感染的调查分析

目的 了解有偿供血员感染丙型肝炎病毒（HCV）、艾滋病病毒（HIV）和乙型肝炎病毒（HBV）的情况,分析HCV和HIV感染对HBsAg的影响。方法 检测296名供血员血清抗－HCV、抗－HIV和HBV的5项标志物（HBsAg、抗－HBs、HBeAg抗－HBe及抗－HBc）。结果 296例有偿供血员中,抗－HCV阳性194例,占65.5%。抗－HCV阳性者中,抗－HIV阳性为145例,占HCV总阳性的75％。本组AIDS患者均死于肝外感染或肿瘤而非肝病。HCV合并HIV感染组的HBsAg阳性率为2.8%,明显低于单纯HCV和单纯HIV感染者（10％）,两组比较差异有显著性（P＜0.05）。结论 在HIV高发区,抗－HCV阳性有偿献血员常合并HIV感染,是AIDS高危人群。HCV合并HIV感染,可能干扰HBsAg的合成。     

HIV感染合并慢性乙型、丙型肝炎的治疗(欧洲会议共识介绍)

全球有3．7～4亿的乙型肝炎病毒（HBV）携带者和超过1．8亿的丙型肝炎病毒（HCV）携带者。由于两者与HIV有共同的传播途径，因而有大量的患者合并HIV感染。全球约有几百万人合并感染HBV／HCV和HIV。在欧洲，约40％的HCV感染者以及8％的HBsAg阳性者合并HIV感染。     

194例HIV阳性孕妇HBV HCV及梅毒合并感染状况分析

目的了解广西艾滋病病毒(HIV)阳性孕妇合并感染乙型肝炎病毒(HBV)、丙型肝炎病毒(HCV)、梅毒状况,为医疗部门及相关部门采取有效的措施,实施母婴阻断、提高人口素质提供科学的依据。方法对广西贺州、柳州、南宁和横县发现的194名HIV阳性孕妇的HBV、HCV及梅毒合并感染状况进行检测分析。结果在调查的194名HIV阳性孕妇中,HIV/HCV、HIV/HBV和HIV/梅毒合并感染率分别为14.14%、9.42%和5.24%。2.62%和1.05%的妇女分别有HIV/HBV/HCV和HIV/HCV/梅毒混合感染,吸毒是HIV/HCV合并感染的危险因素,HIV/HBV合并感染存在地区差异。结论研究地区HIV阳性孕妇的HBV、HCV及梅毒感染率显著高于普通孕妇,应早期发现并采取有效的干预措施以预防母婴垂直传播。     

Prevalence of human immunodeficiency virus (HIV), hepatitis B virus, and hepatitis C virus in three groups of populations at high risk of HIV infection in Amritsar (Punjab), Northern India

Three groups of populations at high risk of human immunodeficiency virus (HIV) infection, i.e., injecting drug users (IDUs), truckers, and attendees of sexually transmitted disease (STD) clinic of Amritsar (Punjab), Northern India, were studied in order to determine the prevalence of HIV, hepatitis B virus (HBV), and hepatitis C virus (HCV) infections. Of the 157 IDUs, 16.6, 17.8, and 33.7% were found to be positive for HIV, HBV, and HCV infections, respectively. HCV showed significant difference (P<0.01) and very high rate (8.3%) of co-infection with HIV. In truckers, maximum seropositivity was associated with HIV (19%), i.e., significantly higher than that of HBV (6%, P<0.01) and HCV (3%, P<0.01). In STD clinic attendees, the highest rate of seroprevalence was that of HIV (4.3%), followed closely by that of HBV (3.7%), and HCV (2.6%). The present study emphasizes the need for early screening for HBV and HCV infections of all those also at high risk for HIV infection, and the results highlight the importance of relevant targeted interventions in these populations.     

Study on the blood-borne virus co-infection and T lymphocyte subset among intravenous drug users

AIM: To investigate the features of various blood- borne virus infections and co-infection in intravenous drug users (IDUs), and to examine the correlation of T lymphocyte subsets with virus co-infection. METHODS: Four hundred and six IDUs without any clinical manifestation of hepatitis and 102 healthy persons were enrolled in this study. HBV-DNA and HCV-RNA were detected by fluorescence quantitative PCR. HBsAg, HBeAg, anti-HBc, anti-HCV, HDV-Ag, anti-HGV, anti-HIV, and HCMV-IgM were assayed by enzyme-linked immunosorbent assay (ELISA) and immunochromatographic tests. The levels of Th1 and Th2 cytokines were measured by ELISA and radioactive immune assay (RIA). The T lymphocyte subpopulation was detected by using fluorescence immunoassay. The similar indices taken from the healthy persons served as controls. RESULTS: The viral infection rate among IDUs was 36.45% for HBV, 69.7% for HCV, 47.3% for HIV, 2.22% for HDV, 1.97% for HGV, and 3.45% for HCMV. The co- infection rate of blood-borne virus was detected in 255 of 406 (62.81%) IDUs. More than 80% (161/192) of subjects infected with HIV were co-infected with the other viruses, such as HBV, HCV. In contrast, among the controls, the infection rate was 17.65% for HBV and 0% for the other viruses. Our investigation showed that there was a profound decrease in the proportion of CD4/CD8 and the percentage of CD3 and CD4, but not in the percentage of CD8. The levels of PHA-induced cytokines (IFN-γ and IL-4) and serum IL-2 were obviously decreased in IDUs. On the other hand, the level ofserum IL-4 was increased. The level of IFN-γ and the percentage of CD4 were continuously decreased when the IDUs were infected with HIV or HIV co-infection. IDUs with HIV and HBV co-infection was 15.1% (29/192). Of those 29 IDU with HIV and HBV co-infection, 51.72% (15/29) and 37.93% (11/29) were HBV-DNA-positive and HBeAg-positive, respectively. But, among IDUs without HIV infection, only 1.68% (2/119) of cases were HBV- DNA-positive. CONCLUSION: HCV, HBV and HIV infections are common in this population of IDU, leading to a high incidence of impaired Th1 cytokine levels and CD4 lymphocyte. IDUs with HIV and HBV/HCV co-infection have lower expression of Th1 cytokine with enhancement of the Th2 response. HIV may be causing HBV replication by decreasing Th1 function.     

Prevalence of occult hepatitis B & C in HIV patients infected through sexual transmission.

BACKGROUND: Prevalence of Hepatitis B virus (HBV) and Hepatitis C virus (HCV) markers including active and occult infection has not been described in diverse cohorts among HIV-infected patients in India. Earlier studies have explained the role of HBV/HCV co-infection in cohorts of injection drug users (IDUs) but the sexual co-transmission of HBV/ HCV is not completely understood. OBJECTIVE: The objective of this study was to assess the prevalence of occult HBV & HCV infection in HIV positive sexually acquired transmission risk group. MATERIALS AND METHODS: 58 sexually acquired HIV positive patients were taken up for the study of occult HBV/HCV co-infection. Data on demographics, sexual behaviour, sexually transmitted diseases (STD), medical history, laboratory tests viz., serum ALT and CD4 count were recorded. HBV serology included HBsAg, anti HBs, IgG anti HBc and HBV DNA (PCR). HCV serology included anti HCV & HCV RNA (RT-PCR). RESULTS: Occult HBV infection (HBV DNA) was observed in 12.2% (7/58 with HBsAg -ve and IgG anti HBc +ve subjects) while an overall prevalence of HBV DNA was 13.7% (12% occult & 1.7% in HBsAg+ve patients). Out of 58 HIV positive patients 29.3% demonstrated reactivity for any marker of past or current HBV infection. (HBsAg 1.7%, anti HBs 10.3% anti HBc IgG 17.2%). 4/58 (6.8%) revealed anti HCV positivity along with HCV RNA positivity by RT-PCR while 6/58 (10.3%) individuals revealed an occult HCV infection (anti HCV negative). The overall HCV RNA prevalence was 17.2%. 2 out of 58 (3.4%) individuals were positive for occult infection of both HBV DNA & HCV RNA (Triple infection HIV/HBV/ HCV). The HBV/HCV co-infected group (n = 18) showed a significantly high ALT (114.3 + 12.3 U/I) & low CD4 count (202.5 + 33.7 cells/mm3). The percent prevalence of HBV/ HCV co-infection was higher in the illiterate group, in men less than 30 years of age, and in those who were married and exhibited polygamous activity. CONCLUSIONS: The study demonstrated that in HIV infected patients testing only serological viral markers like HBsAg, antiHBcIgG & anti HCV, fails to identify the true prevalence of co-infection with HBV & HCV. Qualitative PCR for HBV DNA & HCV RNA detects co-infection in patients who are negative for serological markers. Also, in subjects who had only a sexual risk factor for parenterally transmitted infections, HIV may enhance the sexual transmission of HBV and HCV.     

Rates and impact of hepatitis on human immunodeficiency virus infection in a large African cohort

AIM:To determine the rates and impact of hepatitis B virus(HBV) and hepatitis C virus(HCV) infections on response to long-term highly active antiretroviral therapy(HAART) in a large human immunodeficiency virus(HIV) population in Nigeria.METHODS:HBV and HCV as well as HIV infections are endemic in sub Saharan Africa.This was a retrospective cohort study of 19 408 adults who were recruited between June 2004 and December 2010 in the AIDS Prevention Initiative in Nigeria in Nigeria programme at Jos University Teaching Hospital.Serological assays,including HBV surface antigen(HBsAg) and hepatitis C antibody were used to categorise hepatitis status of the patients.HBsAg was determined using enzyme immunoassay(EIA)(Monolisa HBsAg Ultra3;Bio-Rad).HCV antibody was tested using third generation EIA(DIA.PRO Diagnostic,Bioprobes srl,Milan,Italy).HIV RNA levels were measured using Roche COBAS Amplicor HIV-1 monitor test version 1.5(Roche Diagnostics,GmbH,Mannheim,Germany) with a detection limit of 400 copies/mL.Flow cytometry was used to determine CD4+ cell count(Partec,GmbH Munster,Germany).Comparison of categorical and continuous variables were achieved using Pearson’s χ 2 and Kruskal Wallis tests respectively,on MedCalc for Windows,version 9.5.0.0(MedCalc Software,Mariakerke,Belgium).RESULTS:With an overall hepatitis screening rate of over 90% for each virus;HBV,HCV and HBV/HCV were detected in 3162(17.8%),1983(11.3%) and 453(2.5%) HIV infected adults respectively.The rate of liver disease was low,but highest among HIV monoinfected patients(29,0.11%),followed by HBV coinfected patients(15,0.08%).Patients with HBV coinfection and triple infection had higher log 10 HIV RNA loads(HBV:4.6 copies/mL vs HIV only:4.5 copies/mL,P<0.0001) and more severe immune suppression(HBV:645,55.4%;HBV/HCV:97,56.7%) prior to initiation of HAART compared to HIV mono-infected patients(1852,48.6%)(P<0.0001).Of 3025 patients who were 4.4 years on HAART and whose CD4 cell counts results at baseline and end of follow up were available for     

Suppression of hepatitis C virus (HCV) replication by hepatitis D virus (HDV) in HIV-infected hemophiliacs with chronic hepatitis B and C

Most hemophiliacs who are coinfected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) have high serum levels of HCV RNA. To study the impact of multiple hepatitis virus infections, we evalated all eight chronic carriers of hepatitis B surface antigen (HBsAg) from a previously studied cohort of 99 hemophiliacs with chronic HIV and HCV infections. Stored serum or plasma samples were tested for antibody to hepatitis D virus (anti-HDV) by ELISA; qualitatively for HCV RNA, HBV DNA, and HDV RNA by the polymerase chain reaction (PCR); and quantitively for HIV RNA, HCV RNA, and hepatitis B virus (HBV) DNA by a quantitative branched DNA signal amplification assay. HCV RNA was detected in only one of five patients with HDV infections on a cross-sectional study, and this individual had low levels (<3.5×10⁵ genome eq/ml) of HCV RNA. In contrast, all three without HDV infections had high levels (>1.5×10⁷ genome eq/ml) of HCV RNA. HIV RNA was present in all eight patients. There was no correlation between the level of HIV RNA and the presence of hepatitis viruses. Three of the eight patients (38%) died of liver failure and another has hypersplenism with hypoprothrombinemia. We conclude that HDV infection appears to suppress HCV replication and that liver failure is common in adult HIV-infected hemophiliacs with chronic HCV and HBV infections. These findings have implications for the therapy of HCV-infected hemophiliacs who are HBsAg positive.This study was supported by the Brandywine Valley Hemophilia Foundation, and the Alice Livingston Trout Family Fund.Dr. Battegay was supported by the Swiss National Science Foundation, the Conrad Gessner Stipendium, and the Schweizerische Stiftung fur medizinisch biologische stipendien.     

2000例门诊和住院患者中HIV与HBV、HCV混合感染的血清学分析

目的分析医院对艾滋病病毒(HIV)抗体筛选结果,了解HIV感染与HBV、HCV肝炎病毒混合感染的关系.方法1998年6月～1999年6月采用ELISA法、MEIA(微粒子酶免法)对HIV、HBV、HCV检测.结果(1)抗HIV感染率为1.4%,其中男性占1.8%,女性占0.9%.民族分布维吾尔族占3.09%,汉族占0.27%,回族占0.77%;维吾尔族与汉族感染率有极显著性差异(χ2=25.34;P＜0.01).(2)在HIV阳性血清中抗HIV单一感染率14.29%;HIV、HCV双重感染率60.71%,HIV、HBV、HCV三重感染率25%;HIV、HCV与HIV、HBV、HCV混合感染率有极显著性差异(χ2=23.9;P＜0.01).结论在本组血清中HIV感染率高,HCV阳性在HIV/AIDS病人血清中混合感染率高,这与青年人静注毒品有关.HIV与HCV有共同传播途径--血液传播.     

Hepatitis B and C virus co-infections in human immunodeficiency virus positive North Indian patients

INTRODUCTION Diseases of the hepatobiliary system are a major problem in patients with human immunodeficiency virus (HIV) infection. An estimated one-third of deaths in HIV patients are directly or indirectly related to liver disease. Liver diseases in HI…     

Seroprevalence of hepatitis B,hepatitis C and human immunodeficiency virus among blood donors,Phitsanulok Regional Blood Center,Thailand

Human immunodeficiency virus (HIV), hepatitis C virus (HCV) and hepatitis B virus (HBV) infections are important blood-borne infections in many countries including Thailand. For epidemiological surveillance and controlling these infections, a cross-sectional group of 2,167 blood donors were screened for HBsAg, antibodies to HCV and HIV by enzyme immunoassay methods. The results revealed that the prevalence of HBsAg positive among studied blood donors was 4.61%, anti-HCV was 2.90% and anti-HIV was 0.69%. When the prevalence was classified by selected socio-demographic variables, it was found that variables including age, gender, marital status and occupation were significant for HBsAg positive rate (p=0.0068, p=0.0019, p=0.0048 and p=0.0017, respectively). For anti-HCV prevalence, studied variables including educational level, occupation and domicile were significant (p<0.0001, p=0.0027, and p<0.0001, respectively), while only educational level was a significant variable for anti-HIV prevalence (p=0.0021). These findings suggest that we should present integrated information and educational programs for preventing and controlling HBV, HCV and HIV transmission among this target group.     

经血液(非静脉吸毒者)和性途径传播的HIV感染者合并HBV和HCV感染的现状

目的 探讨我国经血液(非静脉吸毒者)和性途径传播的HIV感染者合并乙型肝炎和丙型肝炎的状况.方法 回顾性分析2005年1至9月在全国13个研究中心就诊的362例HIV/AIDS患者(静脉吸毒者除外),应用酶联免疫试剂盒分别测定其HBsAg、抗-HBs,HBeAg、抗-Hbe、抗-HBc和抗-HCV.采用t检验和X2检验分别对计量和计数结果进行统计学分析.结果 315例检测血HBV和HCV的患者中,HBsAg阳性14例,占4.4%;抗-HCV阳性158例,占50.2%,抗-HCV阴性157例,占49.8%;HIV、HBV、HCV共感染2例,占0.6%.抗-HCV阳性组中经血液和性传播的比例分别占92%和4%,以血液传播为主;抗-HCV阴性组中经血液和性传播的比例分别占11%和66%,以性传播为主.抗-HCV阳性组的HIV确诊时间、CD4+T淋巴细胞绝对计数、ALT和AST均高于抗-HCV阴性组.两组患者的HBV标志物表达也存在差异,其中抗-HCV阳性组中HBsAg阳性2例,占1.3%,抗-HCV阴性组中HBsAg阳性12例,占7.6%,两组比较差异有统计学意义(X2=7.542,P<0.01).10例HBsAg阳性者进行HBV DNA检测,其中4例阳性,抗-HCV均为阴性.57例抗-HCV阳性患者进行HCV RNA检测,阳性者占63.2%.结论 我国输血和性传播途径的HIV感染合并HBV或HCV感染,以合并HCV感染为主,并多见于经输血感染者.合并HCV感染可加重HIV患者的肝脏损伤,同时也可能存在干扰HBV复制的情况.     

Co-infection by human immuno deficiency virus, hepatitis B and hepatitis C virus in injecting drug users

Injecting drug users (IDUs) are at risk of parenterally transmitted diseases such as hepatitis B virus (HBV) hepatitis C virus (HCV) and human immunodeficiency virus (HIV) infections. The present study was undertaken to find out the prevalence of HIV infection, HBV infection and HCV infection among IDUs of a deaddiction centre. Serum samples from 250, injecting drug users (IDUs) from a de-addiction centre were screened for HBsAg using immunochromatography, anti HCV antibody by 3rd generation ELISA test and anti HIV antibody by ELISA test and immunochromatographic rapid test during the period August to October 2002. One hundred and forty-nine (59.6%) IDUs were positive for HIV antibody, 226 (90.4%) were positive for anti HCV antibody and 27 (10.8%) were positive for HBsAg. There was co-infection of HIV, HBV and HCV in 15 (6%) of the IDUs. The Co-infection of HBV and HCV were found in 12 cases (4.8%) and Co-infection of HIV and HCV was found in 131 cases (52.4%). The IDUs were in sexually active age group with a risk of infection to their sexual partner. There is high prevalence of HCV and HIV infection and co-infection of both viruses among IDUs. Comprehensive public health interventions targeting this population and their sexual partners must be encouraged. Increase coverage of needle, syringe exchange programme (NSEP) to young and new IDUs is required before they are exposed to blood borne viruses.